Amir Quefatieh, MD
Pulmonary Disease · Zephyrhills, FLNPI 1801831755
Payments from drug & device makers
Across 244 payments — averaging $64.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- AstraZeneca$1K
- Takeda Pharmaceuticals U.S.A., Inc.$698
- Olympus Corporation Of The Americas$668
- GSK$623
- Harmony Biosciences LLC$469
- plus $3K from 33 others
What the payments were for
- Travel & lodging$1,60310%
- Food & beverage$5,06732%
- Education$9,03058%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $9,452 |
| AstraZeneca | 35 | $1,048 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $698 |
| Olympus Corporation Of The Americas | 2 | $668 |
| GSK | 36 | $623 |
| Harmony Biosciences LLC | 18 | $469 |
| Actelion Pharmaceuticals US, Inc. | 13 | $369 |
| Inari Medical, Inc. | 5 | $258 |
| Boehringer Ingelheim | 13 | $235 |
| Regeneron Healthcare Solutions, Inc. | 8 | $187 |
| Johnson & Johnson(2 entities) | 2 | $150 |
| Astellas Pharma US Inc | 4 | $143 |
| United Therapeutics Corporation | 7 | $137 |
| Baxter Healthcare | 6 | $127 |
| Sanofi | 6 | $123 |
| Verona Pharma, Inc. | 5 | $107 |
| Mallinckrodt Hospital Products Inc. | 4 | $105 |
| Amgen | 4 | $95 |
| Insmed, Inc. | 4 | $88 |
| Philips North America LLC | 4 | $80 |
| Paratek Pharmaceuticals, Inc. | 4 | $79 |
| Grifols USA, LLC | 3 | $59 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Genentech USA, Inc. | 2 | $33 |
| 3b Medical, Inc. | 2 | $32 |
| Stryker | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Boston Scientific | 1 | $28 |
| Inogen, Inc. | 2 | $25 |
| Medtronic | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $22 |
| CSL Behring | 1 | $20 |
| Pfizer | 1 | $20 |
| Urovant Sciences Inc | 1 | $20 |
| Curonix LLC | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $15 |
| AbbVie | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,405
- FASENRA$449
- AIRSUPRA$449
- BREZTRI$320
- TEZSPIRE$320
- FLOWTRIEVER CATHETER, S$176
- CT THROMBECTOMY SYSTEM KIT$176
- BRILINTA$168
- Monarch Platform$133
How this compares
$15,700 in reported general payments places this provider in the 70th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 62 | $717,625 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 450 | $378,663 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 243 | $182,037 |
| Breo ElliptaFluticasone/Vilanterol | 184 | $82,772 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 219 | $51,302 |
| Advair HfaFluticasone Propion/Salmeterol | 88 | $43,896 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 74 | $40,788 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 64 | $38,886 |
| Pirfenidone | 21 | $34,410 |
| Spiriva RespimatTiotropium Bromide | 60 | $32,097 |
| EliquisApixaban | 31 | $26,340 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $16,883 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 451 | $16,321 |
| Wixela InhubFluticasone Propion/Salmeterol | 96 | $13,015 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $235 | $794,899199 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $623 | $502,223708 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,048 | $198,920308 claims |
| PfizerEliquis | $20 | $26,34031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Zephyrhills
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.